Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.4760
-0.0131 (-2.68%)
At close: Oct 2, 2026, 4:00 PM EDT
0.4748
-0.0012 (-0.25%)
After-hours: Oct 2, 2026, 7:37 PM EDT
Pasithea Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The meeting approved the election of two directors, ratified the independent auditors, and authorized a reverse stock split at a flexible ratio. No questions were raised, and all proposals passed by majority vote.
-
PAZ004, a macrocyclic MEK inhibitor, is advancing through clinical trials for NF1 and advanced cancers, showing a differentiated safety and PK profile with promising early efficacy. The program targets significant unmet needs, especially in cutaneous neurofibroma, and is supported by strong patent protection and recent financing.